Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: Report of two cases

Journal of Infection

Volumn 40, Issue 1, 2000, Pages 94-96

  Mastroianni, C M ^a   D'Ettorre, G ^a   Forcina, G ^a   Corpolongo, A ^a   Dell'Isola, S ^a   Lichtner, M ^a   D'Agostino, C ^a   Trinchieri, V ^a   Santopadre, P ^a   Vullo, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; RITONAVIR; STAVUDINE;

ADULT; ARTICLE; CASE REPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; REMISSION; VISCERAL LEISHMANIASIS;

EID: 0034017213     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.1999.0607     Document Type: Article

References (18)

1. Alvar J., Canavate C., Gutiérrez-Solar B. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 10:1997;298-319.
2. Montalban C., Calleja J. L., Erice A. Visceral leishmaniasis in patients infected with human immunodeficiency virus. J Infect. 21:1990;261-270.
3. Laguna F., Adrados M., Alvar J. Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol & Infect Dis. 16:1997;898-903.
4. Sepkowitz K. A. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet. 351:1998;228-230.
5. Jacobson M. A., French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS. 12 (Suppl A):1998;S157-S163.
6. Carr A., Marriott D., Field A., Vasak E., Cooper D. A. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet. 351:1998;256-261.
7. Valdez H., Gripshover B. M., Salata R. A., Lederman M. M. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS. 12:1998;14-15.
8. Domingo P., Guardiola J. M., Iranzo A., Margall N. Remission of progressive multifocal leukoencephalopathy after antiretroviral therapy. Lancet. 349:1997;1554-1555.
9. McDonald J. C., Torriani F. J., Morse L. S., Karavellas M., Reed J. B., Freeman W. R. Lack of reactivation of cytomegalovirus retinitis after stopping maintenance therapy in AIDS patients with sustained elevation of T cells in response to highly active antiretroviral therapy. J Infect Dis. 77:1998;1182-1187.
10. Aberg J. A., Yajko D. M., Jacobson M. A. Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis. 178:1998;1446-1449.
11. Torre-Cisneros J., Villaneuva J. L., Kindelan J. M., Jurado R., Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients with human immunodeficiency virus. Clin Infect Dis. 17:1993;625-627.
12. Meyerhoff A. U.S. Food and Drug Administration approval of Ambisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 28:1999;42-48.
13. Davidson R. N., Russo R. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotercin B. Clin Infect Dis. 19:1994;560.
14. Pearce E. J., Scott P. A., Sher A. Immune regulation in parasitic infection and disease. Paul W. E. Fundamental Immunology. 1999;1271-1294 Lippincott-Raven, Philadelphia.
15. Albrecht H. Leishmaniosis - new perspectives on an underappreciated opportunistic infection. AIDS. 12:1998;2225-2226.
16. Li T. S., Tubiana R., Calvez V., Ait Mohand H., Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 351:1998;1682-1686.
17. Komanduri K. V., Viswanathan M. N., Wieder E. D. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 4:1998;953-956.
18. Powderly W. G., Landay A., Lederman M. M. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA. 280:1998;72-77.